A new haematological model for the diagnosis and prognosis of severe community-acquired pneumonia: a single-center retrospective study

Xiaoheng Zheng1#, Zena Huang2#, Dong Wang1, Shiyao Pan3, Yating Zhao1, Jin Li1, Jianqing Zhang1, Manman Ye1, Shihong Zhang1

1Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 2Yunkang School of Medicine and Health, Nanfang College, Guangzhou, China; 3Department of Clinical Research & Medical Affairs, Shenzhen Mindray Bio-Medical Electronic Co., Ltd., Shenzhen, China

Contributions: (I) Conception and design: X Zheng, Z Huang; (II) Administrative support: S Zhang; (III) Provision of study materials or patients: D Wang, Y Zhao; (IV) Collection and assembly of data: J Zhang, M Ye; (V) Data analysis and interpretation: S Pan, J Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Background: Severe community-acquired pneumonia (sCAP) is a condition where infection-induced lung tissue inflammation intensifies to a certain stage, resulting in organ dysfunction and even life-threatening disease. When sCAP occurs, neutrophils and monocytes will be activated and released into the peripheral blood to kill bacteria. There are significant morphological changes in these activated neutrophils and monocytes. Haematological parameters can reflect these morphological changes, and indicate the occurrence of sCAP and the severity of infection. This study is designed to establish a new haematological model and explore its clinical value in the diagnosis and prognosis of sCAP.

Methods: Patients who fulfilled the diagnostic criteria of common pneumonia (CP) and sCAP were enrolled in this study. Healthy body check-up patients were also enrolled as a control group. Characteristic information and 28-day survival of patients were recorded. Haematological results, C-reactive protein (CRP) and procalcitonin (PCT) were calculated by BC-6800 Plus automated haematology analyser and cobas E601 automated biochemical immunoassay analyser.

Results: A total of 100 check-ups patients, 100 CP patients, and 111 sCAP patients were enrolled in this study. The new haematological model WBC & Mon-XW, combining WBC (white blood cell count) and Mon-XW (monocytes complexity distribution width), was significantly elevated in the sCAP group and significantly higher than in the control group and the CP group. The new model had good diagnostic efficacy for sCAP, with an area under the receiver operating characteristic curve (ROC-AUC) of 0.842, which was higher than that of CRP (0.633) and PCT (0.750). Moreover, WBC & Mon-XW was effective for survival prognostic evaluations of sCAP, with an ROC-AUC of 0.748. The new model was the independent predictors for the death of pneumonia with an OR (odds ratio) value of 1.82. The 28-day mortality rate was approximately 40% in the WBC & Mon-XW ≥8.9 group, which was approximately 15% higher than that in the WBC & Mon-XW <8.9 group.

Conclusions: The new haematological model can be used as an indicator for sCAP diagnosis and prognosis.

Keywords: Severe community-acquired pneumonia (sCAP); complete blood count (CBC); haematological parameter; diagnosis; prognosis

Submitted Jul 08, 2022. Accepted for publication Aug 08, 2022.
doi: 10.21037/atm-22-3491

View this article at: https://dx.doi.org/10.21037/atm-22-3491
Introduction

Severe community-acquired pneumonia (sCAP) is a condition in which lung tissue (bronchioles, alveoli, and interstitium) inflammation intensifies, resulting in organ dysfunction and even life-threatening diseases (1). sCAP is mainly caused by infection resulting in difficulty breathing, shortness of breath, fever, and tachycardia, and is a leading cause of death from infectious disease worldwide. Patients with sCAP often require intensive care unit (ICU) care, and approximately 25% of these require invasive mechanical ventilation (2). One study showed sCAP patients admitted to ICU had a mortality rate of 35–58%, and was higher with longer ICU stays (3). As a critical condition, sCAP can easily lead to hydration, electrolyte imbalance, and pH problems if left untreated, resulting in multiple organ dysfunction and severe complications including septic shock (4). Therefore, early diagnosis and timely evaluation of the treatment response and prognosis are important role reducing the mortality rate and improving patient outcomes.

Some recent studies analysed different risk factors for sCAP, including age, difficulty swallowing, difficulty breathing, mechanical ventilation, and diabetes (5-9), and established clinical predictive models for its early diagnosis (10-13). However, most risk factors and clinical predictive models are based on clinical findings and clinical symptoms, which are often atypical in patients with sCAP (14,15), affecting their accuracy. While C-reactive protein (CRP), procalcitonin (PCT), and microbial culture are widely used as auxiliary diagnoses of infection, their sensitivity and specificity is relatively low (16-17), as is that of chest imaging, a common clinical approach (18). Therefore, clinicians need a more accurate, objective, and easy-to-use auxiliary diagnostic indicator for the disease. In addition to the infection biomarkers described above, established pneumonia severity assessments include the CURB (confusion, urea, respiratory rate, blood pressure) score, the pneumonia severity index (PSI) score, the Acute Physiology and Chronic Health Evaluation (APACHE) score, the Sequential Organ Failure Assessment (SOFA) score, the Multiple Organ Dysfunction Score (MODS) system, and the PIRO (predisposition, insult, response, organ dysfunction) score. CURB, PSI, and PIRO are used to predict the mortality rate and assess the risk of death, and APACHE, SOFA, and MODS are used to assess the condition and prognosis of critically ill patients, especially those with sepsis. These systems rely on a large amount of medical information, such as underlying physiological status, clinical symptoms, signs, complete blood count (CBC), biochemistry, immunity, imaging, and medications, which complicates the acquisition of complete information for daily assessments.

sCAP is inflammation of the lung tissue caused by infection. When sCAP occurs, neutrophils and monocytes, as the first responders against infection, will be activated and released into the peripheral blood in large quantities to kill bacteria. There are significant morphological differences between activated and non-activated neutrophils and monocytes, such as cell volume, internal complexity and nuclear density. With the development of haematological analyser in recent years, such morphological differences can be identified by haematological analyser and expressed in the form of haematological parameters. Therefore, haematological parameters can reflect the morphological changes of peripheral blood cells, and indicate the occurrence of sCAP and the severity of infection.

The haematological parameters evaluated in this study including cell populations of Neu and Mon, which provide information related to cell complexity, fluorescence intensity and distribution width on DIFF (Differential) channel. The following parameters are reported on the X-axis of DIFF channel scatter-gram: neutrophils cell complexity (Neu-X), monocytes cells complexity (Mon-X), neutrophils complexity distribution width (Neu-XW), and monocytes complexity distribution width (Mon-XW); whereas the following parameters are reported on the y-axis of DIFF channel scatter-gram: neutrophils fluorescence intensity (Neu-Y), monocytes fluorescence intensity (Mon-Y), neutrophils fluorescence intensity distribution width (Neu-YW), monocytes fluorescence intensity distribution width (Mon-YW).

Haematological parameters have been proposed as diagnostic and prognostic indicators for sepsis in recent studies (19-24). However, few studies have focused on the diagnostic and prognostic value of haematological parameters for sCAP. We hypothesised the haematological parameter combining traditional CBC parameters may improve the diagnostic efficacy for sCAP. Therefore, this retrospective study was designed to evaluate the diagnostic and prognostic values of a new haematological model for sCAP, and to compare the new model with other commonly used inflammatory markers. We present the following article in accordance with the STARD reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3491/rc).
Methods

Study design and patient groups

This study was approved by the Independent Ethics Committee (IEC) for Clinical Research and Animal Trials of The First Affiliated Hospital of Sun Yat-sen University [Approval No. (2021)827] and was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent was waived due to the retrospective nature of the study.

A total of 100 healthy subjects, 100 common pneumonia (CP) patients and 111 sCAP patients from our hospital were enrolled in the study between December 2020 and June 2021. The diagnostic gold standard of CP and sCAP referred to the China Expert Consensus on Clinical Practice of Critical and Severe Pneumonia (1) (Table S1 for detailed diagnostic criteria). CP was defined by the following criteria: Chest imaging shows new patchy infiltrative opacities or interstitial changes, with or without pleural effusion. And meets at least one of the following signs: (I) new cough or expectoration or aggravation of existing respiratory symptoms, with purulent sputum, with or without chest pain; (II) fever; (III) signs of pulmonary consolidation and/or wet rales; (IV) WBC >10×10^9/L or <4×10^9/L, with or without a left shift of the nucleus. sCAP was defined by the following criteria: meets at least one of the following criteria: (I) new cough or expectoration or aggravation of existing respiratory symptoms, with purulent sputum, with or without chest pain; (II) fever; (III) signs of pulmonary consolidation and/or wet rales; (IV) WBC >10×10^9/L or <4×10^9/L, with or without a left shift of the nucleus. sCAP patients were divided into a survival group and a death group based on their 28-day survival. ROC curve analysis was performed to compared the values of these parameters.

Statistical analysis

Categorical variables were expressed as absolute numbers and percentages and analysed with chi-square test or Fisher's exact test. Continuous variables were analysed with the Kolmogorov-Smirnov test for normality. Normally distributed data were expressed as the mean and standard deviation (SD) and analysed with analysis of variance (ANOVA) for multigroup comparisons then the Turkey-Kramer test for pairwise comparisons. Nonnormally distributed data were expressed as the median and interquartile range (IQR) and analysed with Kruskal-Wallis nonparametric test for multigroup comparisons then Dunn’s test for pairwise comparisons.

With the sCAP group as the positive group and the CP group as the negative group, logistic regression was used to establish a new haematological model combining WBC and haematological parameter.

To evaluate the clinical value of the new haematological model, CRP, and PCT in patients with sCAP, we built a receiver operating characteristic (ROC) curve and calculated the area under the curve (AUC), with the sCAP group as the positive group and the CP group as the negative group. An optimal threshold based on the Youden index (Youden index = sensitivity + specificity – 1) and the clinical settings was selected to compare the sensitivity and specificity of these parameters.

A two-dimensional scatter plot was drawn with the value of new model as the Y-axis and CRP or PCT as the X-axis to evaluate the relationship between the new model and CRP or PCT.

Pneumonia patients were divided into a survival group and a death group based on their 28-day survival. ROC curve analysis was performed to compared the values of WBC & Mon-XW, CRP and PCT between the two groups. Survival prognosis for sCAP were evaluated by univariate and multivariate logistic regression. In additions, 28-day survival curves were plotted to evaluate the prognostic value of the new model.
SPSS (version 21.0, SPSS Inc., Chicago IL, USA) was used for data statistics, and GraphPad Prism (version 8.0, GraphPad Software, San Diego CA, USA) was used for graphing. All tests were two-sided, and P<0.05 was considered statistically significant.

**Results**

**Characteristics of pneumonia patients**

A total of 211 pneumonia patients were included in this study, including 100 patients (47.4%) in the CP group and 111 patients (52.6%) in the sCAP group (Table 1). The median age was 65.3 years, the proportion of male subjects was higher in the sCAP group (75.7%) than in the CP group (61.0%), 54.1% of patients in the sCAP group had difficulty breathing compared with 11.0% in the CP group (P<0.001), and 66.7% of sCAP patients had pulmonary rales, which was significantly higher than that in the CP group (39.0%, P<0.001).

| Variables                        | Total (N=211) | CP (n=100) | sCAP (n=111) | P     |
|----------------------------------|---------------|------------|--------------|-------|
| Age (years)                      | 65.3±16.0     | 65.6±16.4  | 65.1±15.7    | 0.758 |
| Male                             | 145 (68.7)    | 61 (61.0)  | 84 (75.7)    | <0.050|
| History of hypertension          | 90 (42.7)     | 45 (45.0)  | 45 (40.5)    | 0.513 |
| History of diabetes              | 46 (21.8)     | 20 (20.0)  | 26 (23.4)    | 0.548 |
| History of smoking               | 62 (29.4)     | 25 (25.0)  | 37 (33.3)    | 0.185 |
| History of stroke                | 18 (8.5)      | 10 (10.0)  | 8 (7.2)      | 0.468 |
| History of cardiovascular disease| 22 (10.4)     | 12 (12.0)  | 10 (9.0)     | 0.478 |
| Cough                            | 107 (50.7)    | 55 (55.0)  | 52 (46.8)    | 0.237 |
| Expectoration                    | 100 (47.4)    | 53 (53.0)  | 47 (42.3)    | 0.121 |
| Fever                            | 97 (46.0)     | 42 (42.0)  | 55 (49.5)    | 0.272 |
| Shortness of breath              | 92 (44.7)     | 42 (42.0)  | 50 (46.7)    | 0.535 |
| Difficulty breathing             | 71 (33.6)     | 11 (11.0)  | 60 (54.1)    | <0.001|
| Palpitations                     | 16 (7.6)      | 9 (9.0)    | 7 (6.3)      | 0.461 |
| Chest tightness                  | 58 (27.5)     | 30 (30.0)  | 28 (25.2)    | 0.438 |
| Pulmonary rales                  | 113 (53.5)    | 39 (39.0)  | 74 (66.7)    | <0.001|
| Oedema                           | 39 (18.5)     | 19 (19.0)  | 20 (18.0)    | 0.854 |
| Temperature (°C)                 | 37.2±1.1      | 37.1±1.0   | 37.3±1.1     | 0.297 |
| Diastolic blood pressure (mmHg)  | 87.8±32.5     | 93.1±34.6  | 83.1±2.8     | <0.050|
| Systolic blood pressure (mmHg)   | 113.9±31.1    | 119.9±31.3 | 108.5±30.0   | <0.010|
| Heart rate (bpm)                 | 94.5±19.5     | 89.6±16.2  | 99.0±21.1    | <0.010|
| Respiratory rate (breaths per minute) | 21.4±6.2     | 19.8±2.7   | 22.8±7.9     | <0.010|

Data are represented as mean ± SD or number (%). CP, common pneumonia; sCAP, severe community-acquired pneumonia; SD, standard deviation.

**Haematological parameters for the diagnosis of sCAP**

Table 2 shows all haematological parameters were higher in the two pneumonia groups than in the control group, and all parameters but Mon# (absolute monocyte count) were significantly higher in the sCAP group than in the CP group (P<0.05). Moreover, all parameters but Mon# increased from group 1 to group 3 (Figure 1), and this trend was most pronounced for Mon-XW (P<0.0001 from group 1 to group 2, and from group 2 to group 3).
Table 2 Comparison of parameters among the three groups

| Parameter | Group 1 (n=100) | Group 2 (n=100) | Group 3 (n=111) | P |
|-----------|-----------------|-----------------|-----------------|---|
| WBC       | 6.3 (5.2, 7.1)  | 9.9 (7.4, 13.0) | 12.2 (8.4, 18.5) | <0.0001 |
| Neu#      | 3.4 (2.9, 4.2)  | 8.0 (5.1, 10.8) | 10.2 (6.9, 16.4) | <0.0001 |
| Mon#      | 0.4 (0.3, 0.5)  | 0.6 (0.45, 0.92) | 0.6 (0.27, 0.94) | <0.0001 |
| Neu-X     | 324.8 (311.4, 342.8) | 356.5 (333.5, 377.7) | 368.5 (339.9, 396.4) | <0.0001 |
| Neu-XW    | 227.6 (214.6, 242.7) | 252.6 (235.2, 284.6) | 271.1 (246.3, 307.1) | <0.0001 |
| Neu-Y     | 405.5 (392.2, 419.6) | 447.8 (425.3, 469.7) | 473.7 (443.9, 521.5) | <0.0001 |
| Neu-YW    | 176.7 (170.6, 183.8) | 201.6 (190.2, 211.9) | 216.3 (201.2, 258.8) | <0.0001 |
| Mon-X     | 187.3 (180.5, 191.5) | 209.4 (200.8, 216.2) | 217.5 (208.4, 228.5) | <0.0001 |
| Mon-XW    | 68.5 (66.1, 72.2)  | 80.4 (74.7, 85.9)  | 91.1 (84.0, 103.6)  | <0.0001 |
| Mon-Y     | 902.7 (872.5, 925.6) | 946.2 (901.2, 980.5) | 961.9 (903.2, 1,019.1) | <0.0001 |
| Mon-YW    | 342.8 (321.2, 358.3) | 403.8 (379.6, 441.0) | 454.2 (413.3, 509.1) | <0.0001 |

*, a very significant statistical difference versus other groups (P<0.0001); **, a significant statistical difference versus the CP group (P<0.01) and a very significant statistical difference versus the sCAP group (P<0.0001); †, a very significant statistical difference versus the control group (P<0.01) but no difference versus the sCAP group (P>0.05); ‡, a very significant statistical difference versus the control group (P<0.01) but no difference versus the CP group (P>0.05); §, a very significant statistical difference versus other groups (P<0.01).

WBC, white blood cell count; Neu#, absolute neutrophil count; Mon#, absolute monocyte count; Neu-X, neutrophils cell complexity; Neu-XW, neutrophils complexity distribution width; Neu-Y, neutrophils fluorescence intensity; Neu-YW, neutrophils fluorescence intensity distribution width; Mon-X, monocytes cells complexity; Mon-XW, monocytes complexity distribution width; Mon-Y, monocytes fluorescence intensity; Mon-YW, monocytes fluorescence intensity distribution width; CP, common pneumonia; sCAP, severe community-acquired pneumonia.

ROC analysis was performed to evaluate the diagnostic efficacy of these haematological parameters for sCAP, with a higher AUC value indicating better diagnostic efficacy. The optimal threshold was selected based on the Youden index (Youden index = sensitivity + specificity – 1) and the clinical settings. Table 3 shows the AUCs (sensitivity, specificity) were 0.637 (64%, 60%) for WBC and 0.651 (56.8%, 68%) for Neu# (absolute neutrophil count), both of which are common haematological infection parameters. The diagnostic efficacies of Mon# [0.569 (40.5%, 82.0%)], Neu-X [0.596 (54.1%, 67.0%)], Neu-XW [0.621 (64.0%, 60.0%)], and Mon-Y [0.569 (43.2%, 76.0%)] were weaker than those of WBC and Neu#, while the diagnostic efficacies of Neu-Y [0.688 (54.1%, 77.0%)], Neu-YW [0.714 (62.2%, 75.0%)], Mon-X [0.792 (64.9%, 81.0%)], and Mon-YW [0.736 (81.1%, 56.0%)] were higher than that of WBC and Neu#. Mon-XW had the highest AUC value of 0.792 (64.9%, 81%), indicating the best diagnostic efficacy for sCAP. Based on this result, we combined Mon-XW and the common infection parameter WBC to establish a new haematological model to improve diagnostic efficacy.

Composition of the new haematological model

Figure 2 shows the distribution of WBC and Mon-XW in the two-dimensional scatter plot, vividly demonstrating the effect of combining the two parameters. Samples from the control group are mainly distributed in the lower left area, those from the sCAP group are mainly distributed in the upper right area, and those from the CP group are somewhere in between. The combination of WBC and Mon-XW could separate the three groups, indicating good discrimination.

Logistic regression was performed to build the new haematological model WBC & Mon-XW with WBC and Mon-XW (Table 4). Omnibus tests confirmed the statistical significance of the logistic model (P<0.001) as well as both independent variables (WBC and Mon-XW) (P<0.0001). Each 1-unit increase in WBC was associated with a 9.8% [odds ratio (OR) = 1.098, 1.042–1.157] increase in the risk.
Figure 1 Boxplot comparison of each parameter among the three groups. *, a statistical difference, P<0.05; **, a significant statistical difference, P<0.01; ***, a very significant statistical difference, P<0.0001. NS, no statistical difference; WBC, white blood cell count; Neu#, absolute neutrophil count; Mon#, absolute monocyte count; Neu-X, neutrophils cell complexity; Neu-XW, neutrophils complexity distribution width; Neu-Y, neutrophils fluorescence intensity; Neu-YW, neutrophils fluorescence intensity distribution width; Mon-X, monocytes cells complexity; Mon-XW, monocytes complexity distribution width; Mon-Y, monocytes fluorescence intensity; Mon-YW, monocytes fluorescence intensity distribution width.
of progression to sCAP, and for Mon-XW, the number was 9.2% (OR =1.092, 1.059–1.126).

**New haematological model, CRP, and PCT as diagnostic indicators for sCAP**

In Figure 3 and Table 5, WBC & Mon-XW and CRP were significantly different among and between the three groups (P<0.01), with an increase from group 1 to group 3. PCT was highest in the sCAP group (P<0.05), with no significant difference between the control group and the CP group (P>0.05).

Furthermore, ROC analysis was performed to evaluate the diagnostic efficacy of WBC & Mon-XW, CRP, and PCT for sCAP. The AUC of WBC & Mon-XW was 0.842, and at the cut-off value of 8.47, the sensitivity was 80.2%, and the specificity was 71.0%, which were superior to those of WBC or Mon-XW alone (Figure 4). The AUCs (sensitivity, specificity) for CRP and PCT, two common inflammation indicators, were 0.633 (73.9%, 52%) and 0.750 (72.1%, 63%), respectively, indicating good yet inferior diagnostic efficacy to WBC & Mon-XW (Table 6).

**Table 3 ROC curve results of each parameter**

| Parameter | AUC      | 95% CI         | Cut-off | Sensitivity (%) | Specificity (%) |
|-----------|----------|----------------|---------|-----------------|-----------------|
| WBC       | 0.637    | 0.562–0.712    | 10.6    | 64.0            | 60.0            |
| Neu#      | 0.651    | 0.578–0.725    | 9.6     | 56.8            | 68.0            |
| Mon#      | 0.569    | 0.491–0.648    | 0.4     | 40.5            | 82.0            |
| Neu-X     | 0.596    | 0.519–0.672    | 366.9   | 54.1            | 67.0            |
| Neu-XW    | 0.621    | 0.546–0.697    | 260.4   | 64.0            | 60.0            |
| Neu-Y     | 0.688    | 0.618–0.759    | 470.5   | 54.1            | 77.0            |
| Neu-YW    | 0.714    | 0.645–0.783    | 211.2   | 62.2            | 75.0            |
| Mon-X     | 0.694    | 0.624–0.765    | 216.5   | 54.1            | 78.0            |
| Mon-XW    | 0.792    | 0.733–0.851    | 86.6    | 64.9            | 81.0            |
| Mon-Y     | 0.569    | 0.491–0.647    | 980.6   | 43.2            | 76.0            |
| Mon-YW    | 0.736    | 0.669–0.802    | 407.8   | 81.1            | 56.0            |

ROC, receiver operator characteristic; AUC, area under the curve; CI, confidence interval; WBC, white blood cell count; Neu#, absolute neutrophil count; Mon#, absolute monocyte count; Neu-X, neutrophils cell complexity; Neu-XW, neutrophils complexity distribution width; Neu-Y, neutrophils fluorescence intensity; Neu-YW, neutrophils fluorescence intensity distribution width; Mon-X, monocytes cells complexity; Mon-XW, monocytes complexity distribution width; Mon-Y, monocytes fluorescence intensity; Mon-YW, monocytes fluorescence intensity distribution width; CI, confidence interval.

**Figure 2** WBC and Mon-XW two-dimensional scatter plot. WBC, white blood cell count; Mon-XW, monocytes complexity distribution width.

The new haematological model for the prognostic evaluation of pneumonia patients

ROC analysis was performed to evaluate the survival prognostic performance of WBC & Mon-XW, CRP, and PCT. The AUC of WBC & Mon-XW was 0.842, and at the cut-off value of 8.47, the sensitivity was 80.2%, and the specificity was 71.0%, which were superior to those of WBC or Mon-XW alone (Figure 4). The AUCs (sensitivity, specificity) for CRP and PCT, two common inflammation indicators, were 0.633 (73.9%, 52%) and 0.750 (72.1%, 63%), respectively, indicating good yet inferior diagnostic efficacy to WBC & Mon-XW (Table 6). Figure 5 demonstrates significant positive correlations between the new haematological model and the common inflammation markers CRP and PCT.

At the univariate logistic regression analysis, age (P=0.01), diastolic blood pressure (P=0.003), systolic blood pressure
and WBC & Mon-XW (P<0.001) were found associated with the death of pneumonia. However, at the multivariate analysis age (P=0.001), gender (P=0.04), history of smoking (P<0.001), blood pressure (P<0.001), heart rate (P=0.034) and WBC & Mon-XW (P<0.001) were the independent predictors for the death of pneumonia. The OR values of history of smoking (OR =2.74) and WBC & Mon-XW (OR =1.82) were higher than those of other variables (Table 8).

We followed and recorded the 28-day survival data of 162 pneumonia patients after diagnosis. Patients were divided into the WBC & Mon-XW ≤8.9 (n=81) group and the WBC & Mon-XW ≥8.9 (n=81) group based on WBC & Mon-XW on the day of diagnosis. Twenty-eight-day survival curves were plotted to observe the relationship between patient survival and the new haematological model. By day
28 after diagnosis, 28 of 162 patients (17.3%) died, 20 of whom (71.4%) were in the WBC & Mon-XW ≥8.9 group. Figure 7 shows the 28-day mortality rate was approximately 40% in the WBC & Mon-XW ≥8.9 group, which is approximately 15% higher than that in the WBC & Mon-XW <8.9 group.

Discussion

sCAP is a common critical infectious disease in clinical practice. Patients often suffer from severe disease, progress rapidly, and develop respiratory failure in a short period, and in most cases, simple pulmonary infection rapidly progresses to systemic infection. In addition to pulmonary symptoms, patients often present with sepsis, septic shock, coagulation abnormalities, and multiple organ insufficiency or even failure, with an extremely high mortality rate. Early, rapid, and accurate diagnosis is critical for treatment,
optimal survival, and prognosis. WBC assessment represents an important indicator for clinical judgement of bacterial infection, but its sensitivity and specificity are not yet adequately high. While other auxiliary indicators such as CRP, PCT, and IL-6 are widely used in clinical practice, they have limitations in timeliness and diagnostic efficacy, and cannot meet the needs of clinical diagnosis. Therefore, developing a rapid, effective, accurate, and cost-effective test for sCAP is important.

During bacterial infection, monocytes are activated and play bactericidal and phagocytic roles to defend against pathogenic microorganisms. They play a central role in the immune response against microorganisms and the mechanism of acute infection. As a first-line defence against infection, in addition to phagocytising and killing microorganisms and producing cytokines, monocytes present microbial antigens to T cells, initiating and regulating cellular and humoral immunity. Monocytes activated to play bactericidal roles undergo morphological changes, becoming morphologically different from normal monocytes. This morphological change is a more direct indicator of the body’s stress response and defence mechanism against bacterial invasion and may be used as an accurate auxiliary diagnostic indicator of sCAP. In recent years, haematology analysers have progressed rapidly due to technological advancements. Mindray’s next-generation haematology analyser BC-6800 Plus uses cutting-edge SF-Cube technology for rapid testing of several blood cells and outputs a range of new haematological parameters, which accurately reflect morphological changes in monocytes, indirectly reflecting the infection status of patients.

This study shows Mon-XW has a good diagnostic value for sCAP, with an AUC of 0.792. Its diagnostic efficacy is optimal at a cut-off value of 86.6, and its sensitivity and specificity are 64.9% and 81%, respectively. Therefore, we performed binary logistic regression to linearly combine Mon-XW and WBC to evaluate the value of this new model for sCAP, and the results show it was significantly higher in the sCAP group than in the control group and the CP group (P<0.0001), with a significant difference between the two groups (P<0.0001). Moreover, CRP and PCT were higher in the sCAP group than in the control group (P<0.05). These data indicate the new parameter, CRP, and PCT can be used as auxiliary diagnostic indicators for sCAP and as differential diagnostic indicators between sCAP and CP.

Several studies have shown monocyte haematological

![Figure 6 ROC curve analysis for the 28-days mortality of sCAP.](image)

**Table 7** ROC curve results of each parameter for the death of pneumonia patients

| Parameter         | AUC     | 95% CI       | Cut-off | Sensitivity (%) | Specificity (%) |
|-------------------|---------|--------------|---------|-----------------|-----------------|
| WBC               | 0.644   | 0.522–0.767  | 10.84   | 71.4            | 58.2            |
| Mon-XW            | 0.713   | 0.607–0.819  | 86.1    | 71.4            | 65.7            |
| WBC & Mon-XW      | 0.748   | 0.651–0.845  | 8.9     | 71.4            | 70.9            |
| CRP               | 0.647   | 0.540–0.753  | 70.5    | 75.0            | 52.2            |
| PCT               | 0.647   | 0.535–0.758  | 2.6     | 39.3            | 88.8            |

ROC, receiver operator characteristic; AUC, area under curves; CI, confidence interval; WBC, white blood cell count; Mon-XW, monocytes complexity distribution width; CRP, C-reactive protein; PCT, procalcitonin.
parameters may be indicative of sepsis. Crouser et al. argued that during pathogen invasion, monocytes are activated to fight pathogens, resulting in a rapid increase in their volume. The monocyte distribution width (MDW) reflects this volume change and can be used as an auxiliary diagnostic indicator for sepsis (20). At the threshold of 20.5, its sensitivity is 77%, and specificity is 73%, and combining with WBC further improves diagnostic efficacy, with an ROC-AUC of 0.89. Buoro et al. investigated the correlations between both the neutrophil fluorescence intensity (NE-SFL) and monocyte internal structure (MO-X) with disease severity and found they were most effective in diagnosing sepsis in all patients (AUCs: 0.75, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 0, Survival rate, % Log-rank P<0.001 WBC & Mon-XW <8.9 WBC & Mon-XW ≥8.9 0 5 10 15 20 25 30 Days after disease diagnosis, d Figure 7 The 28-day survival curves of pneumonia patients. WBC, white blood cell count; Mon-XW, monocytes complexity distribution width.

Table 8 Baseline characteristics in pneumonia patients and the multivariate model of death risk by COX regression

| Variables                  | Survivors (N=134) | Non-survivors (N=28) | Univariate | Multivariate |
|----------------------------|-------------------|----------------------|------------|--------------|
| Age (years)                | 64.1±16.9         | 72.4±14.7            | 0.010      | 1.05 (1.02–1.08) | 0.001 |
| Male                       | 87 (64.9)         | 20 (71.4)            | 0.098      | 0.34 (0.13–0.95) | 0.040 |
| History of hypertension    | 57 (42.5)         | 14 (50.0)            | 0.306      |              |      |
| History of diabetes        | 29 (21.6)         | 11 (39.3)            | 0.145      |              |      |
| History of smoking         | 44 (32.8)         | 7 (25.0)             | 0.113      | 2.74 (1.02–7.37) | 0.046 |
| History of stroke          | 10 (7.5)          | 4 (14.3)             | 0.457      |              |      |
| Expectoration              | 68 (50.7)         | 12 (42.9)            | 0.939      |              |      |
| Fever                      | 57 (42.5)         | 15 (53.4)            | 0.685      |              |      |
| Shortness of breath        | 57 (43.2)         | 12 (46.2)            | 0.573      |              |      |
| Difficulty breathing       | 35 (26.1)         | 13 (46.4)            | 0.771      |              |      |
| Chest tightness            | 38 (28.4)         | 5 (17.9)             | 0.627      |              |      |
| Pulmonary rales            | 65 (48.5)         | 17 (60.7)            | 0.068      |              |      |
| Oedema                     | 29 (21.6)         | 4 (14.2)             | 0.093      |              |      |
| Temperature (°C)           | 37.2±1.0          | 37.2±1.42            | 0.624      |              |      |
| Diastolic blood pressure (mmHg) | 91.8±33.1       | 82.8±33.9            | 0.003      | 0.96 (0.95–0.98) | 0.000 |
| Systolic blood pressure (mmHg) | 119.0±30.9       | 97.9±30.8            | 0.000      | 0.95 (0.94–0.97) | 0.000 |
| Heart rate (bpm)           | 92.0±16.4         | 100.9±24.1           | 0.068      | 1.02 (1.01–1.04) | 0.034 |
| Respiratory rate (breaths per minute) | 20.9±5.0        | 23.5±7.2             | 0.887      |              |      |
| CRP                        | 96.3±83.7         | 138.8±93.3           | 0.732      |              |      |
| PCT                        | 4.7±21.0          | 29.8±123.8           | 0.354      |              |      |
| WBC & Mon-XW               | 8.5±1.3           | 9.7±1.6              | 0.002      | 1.82 (1.32–2.52) | 0.000 |

Data are represented as mean ± SD or number (%). OR, odds ratio; CI, confidence interval; CRP, C-reactive protein; PCT, procalcitonin; WBC, white blood cell count; Mon-XW, monocytes complexity distribution width.
0.72, respectively). These parameters were also significantly correlated with the SOFA score, suggesting they may provide useful information for the management of sepsis patients (25). Urrechaga et al. also investigated MO-X in sepsis cases (26), and found that at a threshold of 118.8, its sensitivity, specificity, positive predictive value, and negative predictive value were 78.3%, 84.9%, 58.4%, and 93.5%, respectively, effectively facilitating the diagnosis. Taken together, these data demonstrate the value of haematological parameters in infectious disease.

In addition to good diagnostic efficacy, the new haematological parameter has the following advantages. Firstly, CBC is considered a routine test for daily management and monitoring of patients, and as the new parameter is derived from CBC, no additional samples or costs are required. Secondly, CBC can be completed in five minutes, allowing clinicians to quickly determine the infection status of patients. Thirdly, the haematology analyser is easy to operate and suitable for emergencies at any time of day, and finally, as a quantitative parameter, the new parameter is more objective than manual microscopic observation of morphological changes and the result is more reliable because thousands of cells can be tested at the same time.

This study has some limitations. First, this is a retrospective study, and the level of evidence is relatively low, and multicentre prospective cohort studies are warranted in the future. Second, the new parameter is related to the morphology of blood cells, and the conclusion would be more objective if the results were compared with microscopic observations of standard blood smears. Third, further analysis of the effect of the new parameter on clinical decisions, such as ICU stay and medications, is required.

In short, this study shows the new parameter combining WBC and Mon-XW reflects the infection responses of and morphological changes in neutrophils and monocytes. It can be used for auxiliary diagnosis and prognostic evaluations of sCAP, and has superior diagnostic efficacy compared to CRP and PCT.

Acknowledgments

Funding: The study was supported by National Natural Science Foundation of China (No. 82000355), Guangdong Provincial Natural Science Foundation (No. 2018A030310016), and Guangzhou Science and Technology Program (No. 202102080037).

Footnote

Reporting Checklist: The authors have completed the STARD reporting checklist. Available at https://atm.amegroups.com/article/view/10.21037/atm-22-3491/rc

Data Sharing Statement: Available at https://atm.amegroups.com/article/view/10.21037/atm-22-3491/dss

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3491/coif). SP and JL report that they are working at Shenzhen Mindray Bio-Medical Electronic Co., Ltd. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the IEC for Clinical Research and Animal Trials of The First Affiliated Hospital of Sun Yat-sen University [Approval No. (2021)827]. Informed consent was waived due to the retrospective nature of the study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Emergency Physician Branch of Chinese Medical Doctor Association. Expert Consensus on Clinical Practice of Emergency Severe Pneumonia in China. Chinese Journal of Critical Care Medicine 2016;36:97-107.
2. Garnacho-Montero J, Barrero-Garcia I, Gomez-Prieto MG, et al. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther 2018;16:667-77.
3. Nair GB, Niederman MS. Year in review 2013: critical
4. Ferreira-Coimbra J, Sarda C, Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther 2020;37:1302-18.

5. Finlayson O, Kapral M, Hall R, et al. Risk factors, inpatient care, and outcomes of pneumonia after ischemic stroke. Neurology 2011;77:1338-45.

6. Sui R, Zhang L. Risk factors of stroke-associated pneumonia in Chinese patients. Neurol Res 2011;33:508-13.

7. Huang D, He D, Gong L, et al. Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia and type 2 diabetes mellitus. Crit Care 2021;25:419.

8. Dinh A, Duran C, Ropers J, et al. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open 2021;4:e2129566.

9. Haessler S, Guo N, Deshpande A, et al. Etiology, Treatments, and Outcomes of Patients With Severe Community-Acquired Pneumonia in a Large U.S. Sample. Crit Care Med 2022;50:1063-71.

10. Smith CJ, Bray BD, Hoffman A, et al. Can a novel clinical risk score improve pneumonia prediction in acute stroke care? A UK multicenter cohort study. J Am Heart Assoc 2015:e001307.

11. Florin TA, Ambroggio L, Lorenz D, et al. Development and Internal Validation of a Prediction Model to Risk Stratify Children With Suspected Community-Acquired Pneumonia. Clin Infect Dis 2021;73:e2713-21.

12. Chauvaffard A, Bridevaux PO, Carballo S, et al. Accuracy of a score predicting the presence of an atypical pathogen in hospitalized patients with moderately severe community-acquired pneumonia. BMC Infect Dis 2022;22:424.

13. Ma CM, Wang N, Su QW, et al. Age, Pulse, Urea, and Albumin Score: A Tool for Predicting the Short-Term and Long-Term Outcomes of Community-Acquired Pneumonia Patients With Diabetes. Front Endocrinol (Lausanne) 2022;13:882977.

14. Li L, Zhang LH, Xu WP, et al. Risk assessment of ischemic stroke associated pneumonia. World J Emerg Med 2014;5:209-13.

15. Kishore AK, Vail A, Chamorro A, et al. How is pneumonia diagnosed in clinical stroke research? A systematic review and meta-analysis. Stroke 2015;46:1202-9.

16. Hassan A, Khealani BA, Shaqat S, et al. Stroke-associated pneumonia: microbiological data and outcome. Singapore Med J 2006;47:204-7.

17. Warusevitane A, Karunatilake D, Sim J, et al. Early Diagnosis of Pneumonia in Severe Stroke: Clinical Features and the Diagnostic Role of C-Reactive Protein. PLoS One 2016;11:e0150269.

18. Smith CJ, Kishore AK, Vail A, et al. Diagnosis of Stroke-Associated Pneumonia: Recommendations From the Pneumonia in Stroke Consensus Group. Stroke 2015;46:2335-40.

19. Crouser ED, Parrillo JE, Seymour C, et al. Improved Early Detection of Sepsis in the ED With a Novel Monocyte Distribution Width Biomarker. Chest 2017;152:518-26.

20. Crouser ED, Parrillo JE, Seymour CW, et al. Monocyte Distribution Width: A Novel Indicator of Sepsis-2 and Sepsis-3 in High-Risk Emergency Department Patients. Crit Care Med 2019;47:1018-25.

21. Polilli E, Sozio F, Frattari A, et al. Comparison of Monocyte Distribution Width (MDW) and Procalcitonin for early recognition of sepsis. PLoS One 2020;15:e0227300.

22. Ayres LS, Sgnaolin V, Munhoz TP. Immature granulocytes index as early marker of sepsis. Int J Lab Hematol 2019;41:392-6.

23. Zhang W, Zhang Z, Pan S, et al. The clinical value of hematological neutrophil and monocyte parameters in the diagnosis and identification of sepsis. Ann Transl Med 2021;9:1680.

24. Hausfater P, Boter NR, Indiana MC, et al. Monocyte distribution width (MDW) performance as an early sepsis indicator in the emergency department: comparison with CRP and procalcitonin in a multicenter international European prospective study. Crit Care 2021;25:227.

25. Buoro S, Seghezzi M, Vavassori M, et al. Clinical significance of cell population data (CPD) on Sysmex XN-9000 in septic patients with or without liver impairment. Ann Transl Med 2016;4:418.

26. Urrechaga E, Bóveda O, Aguirre U. Role of leucocytes cell population data in the early detection of sepsis. J Clin Pathol 2018;71:259-66.

(English Language Editor: B. Draper)